Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 188

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Meta‐analysis: esomeprazole or rabeprazole vs. first‐generation pump inhibitors in the treatment of Helicobacter pylori infection

McNicholl, A. G., Linares, P. M., Nyssen, O. P., Calvet, X., Gisbert, J. P.·2012·Alimentary Pharmacology & Therapeutics

Abstract

Summary: Background: The decreasing efficacy of H. pylori eradication treatments over time makes the search for better regimens and adjuvant medications a priority. Aim: To conduct a meta‐analysis of studies comparing rabeprazole or esomeprazole with other proton pump inhibitors ( PPI ) or with each other in H . pylori eradication treatment. Methods: Selection of Studies: Randomised clinical trials comparing esomeprazole or rabeprazole with first‐generation PPI s (omeprazole‐lansoprazole‐pantoprazole) or with each other. Results: The meta‐analysis (35 studies, 5998 patients) showed higher eradication rates for esomeprazole than for first‐generation PPI s: 82.3% vs. 77.6%; OR = 1.32(1.01–1.73); NNT = 21. Rabeprazole also showed better results than first‐generation PPI s: 80.5% vs. 76.2%; OR = 1.21(1.02–1.42); NNT = 23. PPI dosage sub‐analysis: only esomeprazole 40 mg b.d. improved results [83.5% esomeprazole vs. 72.4% first generation; OR = 2.27(1.07–4.82); NNT = 9]. Whereas rabeprazole 10 and 20 mg b.d. maintained results, esomeprazole 20 mg b.d. obtained lower efficacy. Esomeprazole vs. rabeprazole sub‐analysis (five studies): no significant differences were found: 78.7% vs. 76.7%; OR = 0.90(0.70–1.17). CYP 2C19 sub‐analysis: Genotype did not significantly affect eradication either in first [ OR = 1.76(0.99–3.12)] or new generation [ OR = 1.19(0.73–1.95)] PPI s. However, sub‐analysis considering only extensive metaboliser patients showed higher eradication with new‐generation PPI s [ OR = 1.37(1.02–1.84)]. Conclusions: Esomeprazole and rabeprazole show better overall H . pylori eradication rates than first‐generation PPI s. This clinical benefit is more pronounced in esomeprazole 40 mg b.d. regimens. In CYP 2 C 19 extensive metabolisers, new‐generation PPI s are more effective than first‐generation PPI s for H . pylori eradication. However, a general recommendation of using new‐generation PPI s in all scenarios remains unclear.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2036.2012.05211.x

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 188

Metadata

Authors
McNicholl, A. G., Linares, P. M., Nyssen, O. P., Calvet, X., & Gisbert, J. P.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2012-07-15
Volume
36
Issue
5
Pages
414-425
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W2078951211
Cited by
188
References
2
FWCI
12.63
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Meta‐analysis: esomeprazole or rabeprazole vs. first‐generation pump inhibitors in the treatment of Helicobacter pylori infection. https://app.cochat.ai/papers/10.1111/j.1365-2036.2012.05211.x
The paper
McNicholl, A. G., Linares, P. M., Nyssen, O. P., Calvet, X., & Gisbert, J. P. (2012). Meta‐analysis: esomeprazole or rabeprazole vs. first‐generation pump inhibitors in the treatment of Helicobacter pylori infection. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/j.1365-2036.2012.05211.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.